New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 21, 2012
07:38 EDTHZNPHorizon Pharma to receive approval from UK MHRA
Horizon Pharma announced that the United Kingdom Medicines and Healthcare products Regulatory Agency, or MHRA, based on the favorable recommendation of their Commission on Human Medicines (CHM), will grant a Marketing Authorization for Duexis, pending review of updated licensing documents which the Company has provided to the MHRA. The MA of Duexis is for the treatment of osteoarthritis, or OA, rheumatoid arthritis, or RA, and ankylosing spondylitis, or AS, and to decrease the risk of developing upper gastrointestinal ulcers. Duexis is approved and available in the United States.
News For HZNP From The Last 14 Days
Check below for free stories on HZNP the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
August 13, 2014
07:32 EDTHZNPHorizon Pharma, POZEN announce USPTO Notice of Allowance for VIMOVO
Subscribe for More Information
August 8, 2014
10:34 EDTHZNPOptions with decreasing implied volatility
Subscribe for More Information
07:35 EDTHZNPHorizon announces S-4 registration statement for Vidara declared effective
Subscribe for More Information
August 7, 2014
17:13 EDTHZNPVisium reports 5.5% passive stake in Horizon Pharma
Subscribe for More Information
10:20 EDTHZNPHigh option volume stocks
Subscribe for More Information
09:08 EDTHZNPOn The Fly: Pre-market Movers
Subscribe for More Information
06:46 EDTHZNPHorizon Pharma sees FY15 revenue $380M-$405M, consensus $351.77M
Subscribe for More Information
06:45 EDTHZNPHorizon Pharma backs FY14 revenue guidance of $270M-$280M, consensus $268.95M
Backs adjusted EBITDA guidance of $80M-$90M.
06:43 EDTHZNPHorizon Pharma reports Q2 adjusted EPS 21c, consensus 10c
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use